Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C Virus

Despite direct acting antivirals (DAAs) curing >95% of individuals infected with hepatitis C (HCV), in order to achieve the World Health Organization HCV Global Elimination Goals by 2030 there are still major challenges that need to be overcome. DAAs alone are unlikely to eliminate HCV in the abs...

Descripción completa

Detalles Bibliográficos
Autores principales: Gummow, Jason, Masavuli, Makutiro G., Mekonnen, Zelalem A., Li, Yanrui, Wijesundara, Danushka K., Shrestha, Ashish C., Voskoboinik, Ilia, Gowans, Eric J., Grubor-Bauk, Branka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158683/
https://www.ncbi.nlm.nih.gov/pubmed/32013228
http://dx.doi.org/10.3390/vaccines8010053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158683/
https://www.ncbi.nlm.nih.gov/pubmed/32013228
http://dx.doi.org/10.3390/vaccines8010053

Ejemplares similares